PPARGC1A and metabolic dysfunction-associated steatotic liver disease: Consistent with a previous study, the increased expression of PGC-1α and CPT-1α ameliorated NAFLD by promoting mitochondrial function (31), with GAS5 knockdown increasing the expression of PGC-1α and CPT-1α.